By NewsDesk @infectiousdiseasenews
Morristown, NJ pharmaceutical company, Melinta Therapeutics announced this week that their lipoglycopeptide antibiotic, KIMYRSA™ (oritavancin), is now commercially...
Melinta Therapeutics, LLC (Melinta), today announced that the U.S. Food and Drug Administration (FDA) has approved KIMYRSA™ (oritavancin) for the treatment of adult patients with acute bacterial skin...
Strictly Necessary Cookies
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.